WOMEN’S HEALTH INITIATIVE UPDATE: Surprise! Menopausal Symptoms Return After Stopping HT
Jane E. Corboy
Abstract
Jane E. Corboy
Abstract
This is another report from the discontinued, estrogen-progestin arm of the WHI's hormone therapy trial. In this arm, 16,608 postmenopausal women who had not had hysterectomy were randomized to receive either conjugated estrogens (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day) or placebo (Journal Watch Women's Health Aug 7 2002). Clinicians are well aware that menopausal symptoms are likely to return in women who discontinue HT, but which …
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This is another report from the discontinued, estrogen-progestin arm of the WHI's hormone therapy trial. In this arm, 16,608 postmenopausal women who had not had hysterectomy were randomized to receive either conjugated estrogens (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day) or placebo (Journal Watch Women's Health Aug 7 2002). Clinicians are well aware that menopausal symptoms are likely to return in women who discontinue HT, but which …
Key concepts: Medroxyprogesterone acetate, Medicine, Women's Health Initiative, Progestin, Placebo, Hormone therapy, Estrogen, Medroxyprogesterone